550 results match your criteria Urticaria Cholinergic


Cytisine induced urticaria : a case report during a smoking cessation treatment.

Acta Biomed 2022 Jun 22;93(S1):e2022073. Epub 2022 Jun 22.

Department of Medicine, Addiction Medicine Unit, Verona University Hospital, 37134 Verona, Italy .

Cytisine is considered to be the oldest medication for smoking cessation and has been used for this purpose in some Eastern/Central European and Central Asian countries for over 50 years. Several sources points towards cytisine's efficacy and effectiveness; it's well tolerated when taken at the recommended dose, and adverse events reported in trials are typically non-serious and self-limiting gastrointestinal and sleep disturbances. We report a suspect case of urticaria during treatment for smoking cessation with cytisine in a woman of 48 years treated for smoking at the Unit of Addiction Medicine, Department of Internal Medicine, Hospital Trust of Verona, Italy. Read More

View Article and Full-Text PDF

Use of Danazol in the rare debilitating condition acquired idiopathic generalised anhidrosis.

Australas J Dermatol 2022 05 27;63(2):e170-e173. Epub 2022 Mar 27.

Department of Dermatology, Alfred Health, Melbourne, Victoria, Australia.

View Article and Full-Text PDF

Anhidrosis accompanied by cholinergic urticaria-like rash and dermal pain in a patient with Sjögren's syndrome.

J Dermatol 2022 Jun 22;49(6):666-670. Epub 2022 Mar 22.

Department of Dermatology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.

Cholinergic urticaria (CholU)-like rash and dermal pain on sweating occur in patients with acquired idiopathic generalized anhidrosis (AIGA). However, it is unclear whether these are symptoms specific to AIGA among the various types of acquired generalized anhidrosis/hypohidrosis (AGAH). Moreover, the pathogenesis underlying CholU-like rash and dermal pain observed with anhidrosis remains to be clarified. Read More

View Article and Full-Text PDF

Cyclosporine in Cholinergic Itch.

Indian Dermatol Online J 2022 Mar-Apr;13(2):234-236. Epub 2022 Mar 3.

Department of Dermatology, R.N.T. Medical College, Udaipur, Rajasthan, India.

Cholinergic itch is part of symptom complex that also includes cholinergic erythema and cholinergic urticaria. It mostly occurs during the winters among young adults. It is characterized by onset of severe itching or burning sensation all over body, mostly, on exposure to sunlight, warm atmosphere and in some cases after hot and spicy food intake. Read More

View Article and Full-Text PDF

Clinical and histological characterization of transient dermal pain triggered by sweating stimuli.

Allergol Int 2022 Mar 7. Epub 2022 Mar 7.

Department of Dermatology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan. Electronic address:

Background: Tingling dermal pain triggered by sweating impairs the lives of patients with cholinergic urticaria and generalized anhidrosis. However, dermal pain evoked by sweating stimuli has been under investigated.

Methods: To clarify characteristics of tingling dermal pain on sweating, we retrospectively evaluated clinical and histopathological manifestations in 30 patients having the main problem of dermal pain on sweating, and the efficacy of treatments. Read More

View Article and Full-Text PDF

Cholinergic Urticaria, an Effective and Safe "Off Label" Use of Dupilumab: A Case Report with Literature Review.

Clin Cosmet Investig Dermatol 2022 18;15:253-260. Epub 2022 Feb 18.

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Cholinergic Urticaria (CholU) is a form of generalized urticaria induced by an increase in core body temperature that activates the sweat reflex. Clinically it is characterized by localized and highly itchy wheals with surrounding erythema and can occur in response to exercise, hot baths and/or emotional stress. Dupilumab is a fully human monoclonal antibody specifically designed to simultaneously inhibit the activity of interleukin-4 (IL-4) and interleukin-13 (IL-13), which play a key role in the inflammation cascade of type 2. Read More

View Article and Full-Text PDF
February 2022

Efficacy and safety of ebastine dose escalation in chronic urticaria: A prospective study.

Dermatol Ther 2022 May 8;35(5):e15386. Epub 2022 Mar 8.

Dermatology and Plastic Surgery Center, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.

The second-generation antihistamines at licensed doses are first-line treatment in urticaria and up-dosing is recommended as second-line treatment. To assess the efficacy and safety of escalated doses of ebastine in patients with chronic urticaria (CU), we designed this study. Recruited patients with CU were treated with increasing doses of ebstine. Read More

View Article and Full-Text PDF

An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.

J Allergy Clin Immunol 2022 May 23;149(5):1683-1690.e7. Epub 2021 Dec 23.

Dermatologial Allergology, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany; Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany. Electronic address:

Background: Chronic urticaria (CU) is a debilitating mast cell-driven disease, often refractory to standard therapy (ie, antihistamines). Lirentelimab, an anti-sialic acid-binding immunoglobulin-like lectin 8 mAb, selectively inhibits mast cells and depletes eosinophils.

Objective: We sought to determine safety and efficacy of lirentelimab in patients with CU. Read More

View Article and Full-Text PDF

[ADVANCES IN THE TREATMENT AND ELUCIDATION OF THE PATHOPHYSIOLOGY OF CHRONIC URTICARIA].

Authors:
Atsushi Fukunaga

Arerugi 2021;70(10):1363-1370

Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine.

View Article and Full-Text PDF
January 2022

An evaluation of the factors affecting the clinical and laboratory findings, prognosis, and treatment response in children with chronic urticaria.

Dermatol Ther 2022 03 21;35(3):e15261. Epub 2021 Dec 21.

Department of Pediatrics, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey.

Chronic urticaria (CU) is a rare disease in childhood, and studies in children are limited. In this study, the aim was to investigate the clinical and laboratory findings and demographic characteristics of children with CU and to determine the factors affecting prognosis. The study included 141 patients aged 0-18 years who were diagnosed with CU in the pediatric allergy outpatient clinic between January 1, 2013, and December 31, 2018. Read More

View Article and Full-Text PDF

The widely used antihistamine mepyramine causes topical pain relief through direct blockade of nociceptor sodium channels.

FASEB J 2021 12;35(12):e22025

Laboratoire de Neurosciences Cognitives, UMR 7291, CNRS, Aix-Marseille-Université, Marseille Cedex 15, France.

Mepyramine, a first-generation antihistamine targeting the histamine H(1) receptor, was extensively prescribed to patients suffering from allergic reactions and urticaria. Serious adverse effects, especially in case of overdose, were frequently reported, including drowsiness, impaired thinking, convulsion, and coma. Many of these side effects were associated with the blockade of histaminergic or cholinergic receptors. Read More

View Article and Full-Text PDF
December 2021

Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis.

Allergy Asthma Clin Immunol 2021 Oct 16;17(1):109. Epub 2021 Oct 16.

College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Background: Currently there is no systematic review and meta-analysis of the global incidence rates of anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines in the general adult population.

Objectives: To estimate the incidence rates of anaphylactic and nonanaphylactic reactions after COVID-19 vaccines and describe the demographic and clinical characteristics, triggers, presenting signs and symptoms, treatment and clinical course of confirmed cases.

Design: A systematic review and meta-analysis. Read More

View Article and Full-Text PDF
October 2021

A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.

Trials 2021 Oct 11;22(1):694. Epub 2021 Oct 11.

Julius Clinical, Zeist, the Netherlands.

Objectives: It is currently thought that most-but not all-individuals infected with SARS-CoV-2 develop symptoms, but the infectious period starts on average 2 days before the first overt symptoms appear. It is estimated that pre- and asymptomatic individuals are responsible for more than half of all transmissions. By detecting infected individuals before they have overt symptoms, wearable devices could potentially and significantly reduce the proportion of transmissions by pre-symptomatic individuals. Read More

View Article and Full-Text PDF
October 2021

Efficiency and safety of desloratadine in combination with compound glycyrrhizin in the treatment of chronic urticaria: a meta-analysis and systematic review of randomised controlled trials.

Pharm Biol 2021 Dec;59(1):1276-1285

School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Context: Desloratadine, an H1 receptor antagonist, is suggested as an effective first-line drug for chronic urticarial (CU). However, the efficacy of desloratadine alone is limited, and the recurrence rate of CU is relatively high.

Objective: We sought to evaluate the efficacy and clinical feasibility of desloratadine in combination with compound glycyrrhizin in the treatment of CU. Read More

View Article and Full-Text PDF
December 2021

Acquired Idiopathic Generalized Anhidrosis (AIGA) and Its Complications: Implications for AIGA as an Autoimmune Disease.

Int J Mol Sci 2021 Aug 4;22(16). Epub 2021 Aug 4.

Allergic Disease Research Center and Department of Dermatology, Chutoen General Medical Center, Kakegawa 436-8555, Japan.

Acquired idiopathic generalized anhidrosis (AIGA) is a rare disorder in which systemic anhidrosis/hypohidrosis occurs without causative dermatological, metabolic or neurological disorder. Most cases of AIGA have been reported in Asia, especially in Japan, but there have been only a few reports in Europe and the United States. Severe AIGA may result in heatstroke and can reduce quality of life due to restriction of exercise and outdoor works. Read More

View Article and Full-Text PDF

Food-dependent and food-exacerbated symptomatic dermographism: New variants of symptomatic dermographism.

J Allergy Clin Immunol 2022 02 8;149(2):788-790. Epub 2021 Aug 8.

Urticaria Center of Reference and Excellence (UCARE), Dermatological Allergology, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Background: Symptomatic dermographism (SD) is the most common form of chronic inducible urticaria. The criterion standard for diagnosing SD and disease activity assessment in SD is provocation testing. As of now, if and what cofactors have an impact on provocation test results is unknown. Read More

View Article and Full-Text PDF
February 2022

Omalizumab in chronic inducible urticaria: A retrospective, real-life study.

Ann Dermatol Venereol 2021 12 8;148(4):262-265. Epub 2021 Jul 8.

Service de dermatologie, CHU de Lille, 59000 Lille, France; Inserm, U1286 - INFINITE - Institute for Translational Research in Inflammation, CHU de Lille, University Lille, 59000 Lille, France.

View Article and Full-Text PDF
December 2021

A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.

Trials 2021 Jun 22;22(1):412. Epub 2021 Jun 22.

Julius Clinical, Zeist, the Netherlands.

Objectives: It is currently thought that most-but not all-individuals infected with SARS-CoV-2 develop symptoms, but that the infectious period starts on average two days before the first overt symptoms appear. It is estimated that pre- and asymptomatic individuals are responsible for more than half of all transmissions. By detecting infected individuals before they have overt symptoms, wearable devices could potentially and significantly reduce the proportion of transmissions by pre-symptomatic individuals. Read More

View Article and Full-Text PDF

Acetylcholine-induced whealing in cholinergic urticaria - What does it tell us?

J Dermatol Sci 2021 Jul 7;103(1):10-15. Epub 2021 May 7.

Dermatological Allergology, Allergie-Centrum-Charité, Dpt. of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany. Electronic address:

Background: Cholinergic urticaria (CholU) is characterized by the occurrence of itchy wheals induced by sweating. Intradermal injections of acetylcholine (ACh) have been proposed to help with diagnosing CholU and subgrouping of patients, but controlled studies are largely missing.

Objective: To compare the rates of positive ACh test results in well characterized CholU patients and controls and to identify clinical features of CholU linked to ACh reactivity. Read More

View Article and Full-Text PDF

Anaphylaxis After the Covid-19 Vaccine in a Patient With Cholinergic Urticaria.

Mil Med 2021 Apr 14. Epub 2021 Apr 14.

Department of Allergy and Immunology, Walter Reed National Military Medical Center, Bethesda, MD 20892, USA.

Cholinergic urticaria is a common disorder that has been associated with anaphylaxis. We report the events, workup, and eventual second dose vaccination of a patient at the Walter Reed National Military Medical Center, who had immediate anaphylaxis after administration of the first Pfizer-BioNTech Covid-19 (BNT162b2) vaccine dose. During the initial evaluation after anaphylaxis, the patient described a history of symptoms suspicious for cholinergic urticaria but had never had this condition confirmed with standardized testing. Read More

View Article and Full-Text PDF

Clinical Characteristics, Management, and Natural History of Chronic Inducible Urticaria in a Pediatric Cohort.

Int Arch Allergy Immunol 2021 1;182(8):757-764. Epub 2021 Apr 1.

Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Center, Montreal, Québec, Canada.

Background: Some forms of chronic urticaria (CU) can be specifically attributed to a response to a definite trigger, referred to as chronic inducible urticaria (CIndU). We aimed to assess the demographics, clinical characteristics, comorbidities, natural history, and management of pediatric patients with CIndU.

Methods: Over a 6-year period, children presenting to the allergy clinic at the Montreal Children's Hospital (MCH) with CIndU were prospectively recruited. Read More

View Article and Full-Text PDF
September 2021

Comparative Efficacy of Fexofenadine Versus Levocetrizine Versus Desloratadine via 1% Histamine Wheal Suppression Test.

Kathmandu Univ Med J (KUMJ) 2020 Jan.-Mar;18(69):19-22

Department of Dermatology, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.

Background Urticaria and allergic dermatoses remains a great challenge to treating dermatologist. Histamine is the major mediator in such disorders. Antihistamines as levocetrizine, fexofenadine and desloratadine are often used to treat such conditions. Read More

View Article and Full-Text PDF
February 2021

Solifenacin-induced acute urticaria and angioedema: a rare adverse effect.

Postgrad Med J 2022 Jun 15;98(1160):420-421. Epub 2021 Jan 15.

Physical Medicine & Rehabilitation, Armed Forces Institute of Rehabilitation Medicine, Rawalpindi, Pakistan.

Antimuscarinics are first-line medication for management of overactive bladder with solifenacin being commonly prescribed. Angioedema is the swelling of mucosa and submucosal tissue. There are no published case reports of drug-induced angioedema involving solifenacin. Read More

View Article and Full-Text PDF

Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses.

BMC Vet Res 2020 Oct 1;16(1):368. Epub 2020 Oct 1.

K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California-Davis, CA, 95616, Davis, USA.

Background: Meperidine is a synthetic opioid that belongs to the phenylpiperidine class and is a weak mu receptor agonist. In horses there are a limited number of published studies describing the analgesic effects of systemically administered meperidine in horses. The objective of this study was to describe the pharmacokinetics, behavioral and physiologic effects and effect on thermal threshold of three doses of intravenously administered meperidine to horses. Read More

View Article and Full-Text PDF
October 2020

Chronic inducible urticaria: classification and prominent features of physical and non-physical types.

Acta Dermatovenerol Alp Pannonica Adriat 2020 Sep;29(3):141-148

Clinical Department of Dermatovenereology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.

Chronic inducible urticaria (CIndU) is a common inflammatory skin condition characterized by the recurrence of itchy wheals and/or angioedema that lasts more than 6 weeks and is induced by specific physical or environmental stimuli (cold, heat, exercise, pressure, sunlight, vibration, water, etc.). According to the current international classification, it includes physical urticarias (dermographism, delayed-pressure urticaria, exercise-induced urticaria, cold urticaria, heat urticaria, solar urticaria, and vibratory urticaria) and non-physical urticarias caused by exposure to specific stimuli (cholinergic urticaria, contact urticaria, and aquagenic urticaria). Read More

View Article and Full-Text PDF
September 2020

[Treatment of simultaneously occurring urticaria and atopic dermatitis with dupilumab].

Hautarzt 2021 Mar;72(3):249-251

Dermatologische Praxis Dr. Herbst & Kollegen, Rheinstr. 7-9, 64283, Darmstadt, Deutschland.

Our 21-year-old woman presented with symptoms of chronic spontaneous urticaria with angioedema and of cholinergic urticaria as well as of atopic dermatitis. Treatment with the IgE antibody omalizumab resulted in an improvement of urticaria; however, relapses of the atopic dermatitis occurred. The use of the monoclonal IL-4/13 receptor antibody dupilumab resulted in complete healing of the atopic dermatitis, complete remission of the chronic spontaneous urticaria with angioedema, and the satisfactory control of cholinergic flare ups over a follow-up period of 26 weeks. Read More

View Article and Full-Text PDF

MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous Urticaria.

J Invest Dermatol 2021 03 7;141(3):678-681.e2. Epub 2020 Aug 7.

Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article and Full-Text PDF

Chronic inducible urticaria subtypes in children: Clinical features and prognosis.

Pediatr Allergy Immunol 2021 01 24;32(1):146-152. Epub 2020 Aug 24.

Department of Pediatric Allergy, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Background: Chronic inducible urticaria (CIndU) is a subtype of chronic urticaria induced by a physical stimulus.

Objective: To evaluate the clinical features, prognostic factors, and natural course of childhood CIndU subtypes.

Methods: Patients (1-18 years old, n = 117) diagnosed with CIndU between March 2011 and March 2019 were analyzed. Read More

View Article and Full-Text PDF
January 2021

Chronic inducible urticaria: confirmation through challenge tests and response to treatment.

Einstein (Sao Paulo) 2020 10;18:eAO5175. Epub 2020 Jul 10.

Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Objective To evaluate the positivity of challenge tests of patients suspected of chronic inducible urticaria and the response to treatment. Methods A retrospective study of electronic medical records of patients suspected of chronic inducible urticaria. All patients were submitted to challenge tests with triggering stimuli, according to the clinical history and, subsequently, the response to drug treatment was evaluated. Read More

View Article and Full-Text PDF

Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature.

Dermatol Ther 2020 11 11;33(6):e14010. Epub 2020 Aug 11.

Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.

To examine the effectiveness of omalizumab on disease activity and quality of life in patients with cholinergic urticaria (CholU). Further, a systematic review of the literature was performed to identify all studies of use of omalizumab in CholU. A total of 23 patients (63. Read More

View Article and Full-Text PDF
November 2020